89 related articles for article (PubMed ID: 19194578)
1. Radiolytic activation of a cytarabine prodrug possessing a 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics.
Hirata N; Fujisawa Y; Tanabe K; Harada H; Hiraoka M; Nishimoto S
Org Biomol Chem; 2009 Feb; 7(4):651-4. PubMed ID: 19194578
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and one-electron reduction characteristics of radiation-activated prodrugs possessing two 5-fluorodeoxyuridine units.
Tanabe K; Sugiura M; Ito T; Nishimoto S
Bioorg Med Chem; 2012 Sep; 20(17):5164-8. PubMed ID: 22847019
[TBL] [Abstract][Full Text] [Related]
3. Stereoelectronic effect on one-electron reductive release of 5-fluorouracil from 5-fluoro-1-(2-oxocycloalkyl)uracils as a new class of radiation-activated antitumor prodrugs.
Mori M; Hatta H; Nishimoto S
J Org Chem; 2000 Jul; 65(15):4641-7. PubMed ID: 10959869
[TBL] [Abstract][Full Text] [Related]
4. Reductive activation of 5-fluorodeoxyuridine prodrug possessing azide methyl group by hypoxic X-irradiation.
Tanabe K; Ishizaki J; Ando Y; Ito T; Nishimoto S
Bioorg Med Chem Lett; 2012 Feb; 22(4):1682-5. PubMed ID: 22248856
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation.
Shibamoto Y; Tachi Y; Tanabe K; Hatta H; Nishimoto S
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):397-402. PubMed ID: 14751508
[TBL] [Abstract][Full Text] [Related]
6. A preclinical evaluation of cytarabine prodrug nanofibers assembled from cytarabine-lauric acid conjugate toward solid tumors.
Liu R; Jiang Y; Hu X; Wu J; Jiang W; Jin G; Luan Y
Int J Pharm; 2018 Dec; 552(1-2):111-118. PubMed ID: 30268848
[TBL] [Abstract][Full Text] [Related]
7. Radiolytic one-electron reduction characteristics of tyrosine derivative caged by 2-oxopropyl group.
Tanabe K; Ebihara M; Hirata N; Nishimoto S
Bioorg Med Chem Lett; 2008 Dec; 18(23):6126-9. PubMed ID: 18930655
[TBL] [Abstract][Full Text] [Related]
8. Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential.
Denora N; Laquintana V; Trapani A; Lopedota A; Latrofa A; Gallo JM; Trapani G
Mol Pharm; 2010 Dec; 7(6):2255-69. PubMed ID: 20958082
[TBL] [Abstract][Full Text] [Related]
9. 2-Oxoalkyl caged oligonucleotides: one-electron reductive activation into emergence of ordinary hybridization property by hypoxic X-irradiation.
Tanabe K; Kanezaki H; Ishii H; Nishimoto S
Org Biomol Chem; 2007 Apr; 5(8):1242-6. PubMed ID: 17406722
[TBL] [Abstract][Full Text] [Related]
10. Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution.
Gu Y; Jaiswal JK; Wang J; Hicks KO; Hay MP; Wilson WR
J Pharm Sci; 2014 Nov; 103(11):3464-3472. PubMed ID: 25212501
[TBL] [Abstract][Full Text] [Related]
11. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
Wilson WR; Tercel M; Anderson RF; Denny WA
Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
[TBL] [Abstract][Full Text] [Related]
12. A novel class of antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), that releases 5-fluorouracil upon hypoxic irradiation.
Shibamoto Y; Zhou L; Hatta H; Mori M; Nishimoto S
Jpn J Cancer Res; 2000 Apr; 91(4):433-8. PubMed ID: 10804292
[TBL] [Abstract][Full Text] [Related]
13. Nanoassemblies from amphiphilic cytarabine prodrug for leukemia targeted therapy.
Liu J; Zhao D; He W; Zhang H; Li Z; Luan Y
J Colloid Interface Sci; 2017 Feb; 487():239-249. PubMed ID: 27776282
[TBL] [Abstract][Full Text] [Related]
14. Optimization of the auxiliary ligand shell of Cobalt(III)(8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs.
Ahn GO; Ware DC; Denny WA; Wilson WR
Radiat Res; 2004 Sep; 162(3):315-25. PubMed ID: 15333003
[TBL] [Abstract][Full Text] [Related]
15. One-electron reduction characteristics of N(3)-substituted 5-fluorodeoxyuridines synthesized as radiation-activated prodrugs.
Tanabe K; Mimasu Y; Eto A; Tachi Y; Sakakibara S; Mori M; Hatta H; Nishimoto S
Bioorg Med Chem; 2003 Oct; 11(21):4551-6. PubMed ID: 14527551
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic characteristics of L-valyl-ara-C and its implication on the oral delivery of ara-C.
Cheon EP; Han HK
Acta Pharmacol Sin; 2007 Feb; 28(2):268-72. PubMed ID: 17241530
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers.
Sarpietro MG; Ottimo S; Giuffrida MC; Rocco F; Ceruti M; Castelli F
Int J Pharm; 2011 Mar; 406(1-2):69-77. PubMed ID: 21219999
[TBL] [Abstract][Full Text] [Related]
18. Enhanced cellular uptake of Ara-C via a peptidomimetic prodrug, L-valyl-ara-C in Caco-2 cells.
Cheon EP; Hong JH; Han HK
J Pharm Pharmacol; 2006 Jul; 58(7):927-32. PubMed ID: 16805952
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-selective activation of 5-fluorodeoxyuridine prodrug possessing indolequinone structure: radiolytic reduction and cytotoxicity characteristics.
Tanabe K; Makimura Y; Tachi Y; Imagawa-Sato A; Nishimoto S
Bioorg Med Chem Lett; 2005 May; 15(9):2321-4. PubMed ID: 15837317
[TBL] [Abstract][Full Text] [Related]
20. Spiral assembly of amphiphilic cytarabine prodrug assisted by probe sonication: Enhanced therapy index for leukemia.
Liu J; Ma N; Zhao D; Li Z; Luan Y
Colloids Surf B Biointerfaces; 2015 Dec; 136():918-27. PubMed ID: 26551869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
